It was reasoned that IRX4647, an RARγ selective agonist (Fig. 3a), would augment activity of immune checkpoint inhibitors and overcome resistance to anti-PDL-1 treatments in a syngeneic lung cancer model (344SQ in 129sv mice). This evidence concerns the gene RARG and lung cancer.